Kameleon007/iStock via Getty Images
- New Phase 2 data showed that prostate cancer patients who received a Johnson & Johnson combination (New York Stock Exchange:JNJ) Erleada (apalutamide) and androgen deprivation therapy did not see an increase in prostate-specific antigen levels in the blood at 24 months.
- The Apa-RP study evaluated Patients with high-risk localized prostate cancer undergoing radical prostatectomy.
- The results showed that after starting the combination treatment, participants showed a 100% biochemical recurrence (BCR) free rate at 24 months. This means that there is no increase in PSA levels.
- Additionally, the regimen showed a serum testosterone (≥150 ng/dl) recovery rate of 76.4% at 12 months.
- “Despite advances in treatment over the last decade, half of patients with high-risk localized prostate cancer experience disease recurrence less than two years after radical prostatectomy, highlighting the need for options that reduce long-term risks,” said Luca Dezzani, vice president of medicine. Matters, Solid Tumors, Johnson & Johnson Innovative Medicine, said in a declaration.
- J&J (JNJ) noted that up to 50% of patients see prostate cancer come back within ten years of surgery and up to 40% of the approximately 300,000 people diagnosed with prostate cancer each year will be considered high risk.
